ReviewFrontiers in oncology2026
Recent advancement in inflammatory biomarkers for cervical cancer diagnosis and therapy.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cervical cancer (CC) ranks as the fourth most prevalent malignancy among women. High-risk human papillomavirus (HPV) infection is a significant contributor to CC in economically disadvantaged nations. The incidence of CC may be significantly reduced by preventive measures, and early detection is strongly associated with improved survival rates. CC presents a substantial danger to women in low- and middle-income countries who often have severe and untreatable sicknesses due to limited resources. Results: Inflammatory markers, such as platelet count, platelet-to-lymphocyte ratio, and IL-6 tumoral expression, indicate a worse likelihood of survival in individuals with CC. Single nucleotide polymorphisms in cytokine genes have been linked to an increased risk of CC. Cytokines such as IL-12, IL-6, and IL-10 may serve as biomarkers for CC. The prognosis of CC may also be influenced by DNA methylation. Immune cells possess a unique ability to combat tumors, and their interactions with tumor growth and invasion significantly impact prognosis and treatment. Genetic biomarkers, such as circulating cell-free or cellular DNA, RNA, SNPs, and epigenetic biomarkers like microRNA and DNA methylation, have the potential to forecast the likelihood of developing a disease. Protein and cell biomarkers, such as cytokines, hormones, and enzymes, have the potential to detect cancer at an early stage and provide accurate diagnosis and prognosis. Conclusion: This review focuses on evaluating several inflammatory biomarkers with potential use in diagnosing and targeting specific therapeutic interventions for the successful treatment of CC, highlighting the attractive prospects of their medicinal utilization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.